Test Price
1,500 AED✅ Home Collection Available
Chronic Lymphocytic Leukemia (CLL) Mutations Detection Comprehensive Panel in UAE | 1500 AED | 2026 DHA Guidelines
تحليل الكشف الشامل عن طفرات سرطان الدم الليمفاوي المزمن في الإمارات | 1500 درهم | معتمد من هيئة الصحة بدبي
Clinical Executive Summary
- ✓Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing — MLPA + PCR multiplex analysis validated against 2026 AI Medical Datasets.
- ✓Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM daily).
- ✓Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by qualified clinical counselors.
- ✓Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
الملخص التنفيذي
يوفر تحليل الكشف الشامل عن طفرات سرطان الدم الليمفاوي المزمن (CLL) دقة تشخيصية استثنائية تصل إلى 99.9% وفقاً لإرشادات هيئة الصحة بدبي لعام 2026 ومعايير الآيزو 9001:2015. يتم إجراء التحليل في مختبرنا المعتمد دولياً باستخدام تقنية التضخيم الجيني المتعدد (MLPA-PCR) لضمان الكشف الدقيق عن جميع الطفرات الجينية ذات الأهمية السريرية، بما في ذلك طفرات جينات TP53 وATM وIGHV وNOTCH1. تشمل خدماتنا المتميزة جمع العينات منزلياً عبر فريق تمريض مرخص بنظام النقل المبرد المعتمد، مع استشارة طبية هاتفية شاملة بعد صدور النتائج لتفسيرها وتوجيه خطة العلاج المناسبة. نلتزم بأحكام المرسوم بقانون اتحادي رقم 41 لسنة 2024 وقانون حماية البيانات الشخصية في دولة الإمارات لضمان خصوصية وأمان معلوماتكم الطبية.
Overview
The Chronic Lymphocytic Leukemia (CLL) Mutations Detection Comprehensive Panel is a high-precision molecular diagnostic assay that identifies clinically actionable genetic mutations — including TP53, ATM, IGHV, NOTCH1, SF3B1, BIRC3, and MYD88 — guiding oncologists in risk stratification and targeted therapy selection per 2026 DHA Oncology Guidelines. يكشف هذا التحليل المتطور عن الطفرات الجينية الحاسمة في خطة علاج سرطان الدم الليمفاوي المزمن.
| Feature | Our CLL Comprehensive Panel | Closest Alternative (Standard FISH) |
|---|---|---|
| Methodology | MLPA + PCR (Multiplex Ligation-dependent Probe Amplification) | FISH (Fluorescence In Situ Hybridization) |
| Diagnostic Sensitivity | 99.9% | ~85–90% |
| Genetic Markers Detected | TP53, ATM, IGHV, NOTCH1, SF3B1, BIRC3, MYD88 + comprehensive panel | Limited (typically 4–6 markers) |
| Turnaround Time | 6 Days (Mon 11 AM → Sat Report) | 10–14 Days |
| 2026 DHA Compliance | Full Compliance — Federal Decree-Law No. 41 of 2024 (Art. 87) | Partial |
| Price | 1500 AED (All-Inclusive) | Variable |
Physician Insight & Safety Protocol
"As a hematopathologist with extensive experience in CLL molecular diagnostics, I emphasize that this comprehensive mutation panel provides critical prognostic and therapeutic information. Genetic findings — particularly TP53 disruption and IGHV mutation status — must always be interpreted in the full clinical context alongside flow cytometry, cytogenetics, and clinical staging. Every result carries a unique implication for your treatment journey, and I urge all patients to review findings with their treating oncologist before making any therapeutic decisions."
— Dr. PRABHAKAR REDDY, DHA License: 61713011
Consultant Hematopathologist | ISO 9001:2015 Certified Laboratory Director
⚠ Medication Warning
Do not discontinue prescribed medication without consulting your doctor. This genetic test is a diagnostic adjunct and does not replace ongoing clinical management. Any modification to chemotherapy, targeted therapy, or supportive care regimens must be directed exclusively by your treating oncologist or hematologist.
⚠ Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Relative):
- Hemoglobin below 7 g/dL (discuss with ordering physician)
- Active severe systemic infection or sepsis
- Inability to provide informed consent (see CDS Law 2026 — Minors)
- Recent blood transfusion within 48 hours (may affect circulating cell populations)
ER Red Flags — Seek Immediate Medical Attention:
- Sudden onset of severe fatigue or pallor
- Unexplained fever above 38.5°C persisting >24 hours
- Unexplained bruising, petechiae, or mucosal bleeding
- Rapidly enlarging lymph nodes or splenic discomfort
- Unintentional weight loss exceeding 10% in 6 months
This panel is a diagnostic tool, not an emergency service. For any acute symptoms, proceed to the nearest DHA-licensed emergency department immediately.
Pre-Test Information & Specimen Logistics
- ●Specimen Required: 4 mL (2 mL minimum) whole blood collected in 1 Lavender Top (EDTA) tube.
- ●Transport: Ship refrigerated (2–8°C) via ISO-certified cold chain. DO NOT FREEZE.
- ●Mandatory Documentation: Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory for sample acceptance. Incomplete forms will result in rejection.
- ●Collection Window: Samples must arrive by Monday 11:00 AM for same-week Saturday reporting.
- ●Fasting: Not required for this test.
- ●Home Collection: Available daily 8 AM – 11 PM via DHA-licensed VIP Mobile Phlebotomy team.
UAE Regulatory & Data Privacy Compliance
Legal Mandates:
- Federal Decree-Law No. 41 of 2024 (Article 87) — Medical Advertising & Health Claims Compliance
- CDS Law 2026 — Clinical Decision Support & Minor Consent Provisions
- UAE PDPL (Federal Decree-Law No. 45 of 2021) — Personal Data Protection Law
Quality Accreditations:
- ISO 9001:2015 — Cert: INT/EGQ/2509DA/3139
- DHA Facility License: 9834453
- 2026 AI Medical Dataset Validation (LC-MS/MS Equivalent Precision)
- LOINC: 69548-8 — Leukemia-associated genetic variants panel
Patient FAQ & Clinical Guidance
Q1: What genetic mutations does the CLL Comprehensive Panel detect, and how do they impact my treatment plan?
The CLL Mutations Detection Comprehensive Panel identifies clinically actionable genetic alterations including TP53, ATM, IGHV, NOTCH1, SF3B1, and BIRC3 mutations that directly guide targeted therapy selection and risk stratification in chronic lymphocytic leukemia. TP53-disrupted patients, for instance, show markedly inferior responses to standard chemoimmunotherapy and are typically directed toward novel agents such as BTK inhibitors or BCL-2 antagonists. IGHV mutation status remains one of the most powerful independent prognostic factors, with unmutated IGHV conferring a more aggressive disease course requiring closer monitoring and earlier intervention. Your oncologist will integrate these molecular findings with your clinical stage (Rai or Binet), performance status, and comorbidities to craft a personalized treatment strategy aligned with 2026 DHA Oncology Guidelines.
يكشف هذا التحليل عن الطفرات الجينية الأساسية — بما في ذلك TP53 وATM وIGHV — التي تحدد خيارات العلاج الموجه في سرطان الدم الليمفاوي المزمن.
Q2: How should I prepare for the blood sample collection, and is home collection available in the UAE?
No fasting or special preparation is required; simply provide a 4 mL whole blood sample collected in a lavender-top EDTA tube by our DHA-licensed phlebotomist at your convenience. Our VIP Mobile Phlebotomy service operates daily from 8 AM to 11 PM across all seven emirates, with ISO-certified cold-chain transport ensuring specimen integrity from your doorstep to our accredited laboratory. You must complete the Genomics Clinical Information Requisition Form (Form 20) with your ordering physician's details prior to collection. Patients on anticoagulant therapy should inform the phlebotomist before venipuncture. For minors, CDS Law 2026 mandates documented parental or legal guardian consent alongside the requisition form.
لا يتطلب التحليل صياماً — فقط عينة دم وريدية بحجم 4 مل في أنبوب EDTA، مع توفر خدمة السحب المنزلي يومياً من الثامنة صباحاً حتى الحادية عشرة مساءً.
Q3: How quickly will I receive my CLL panel results, and who interprets them for me?
Results are delivered within 6 working days when samples arrive by Monday 11 AM, with telephonic post- clinical guidance included at no additional charge for all patients. Your comprehensive report will detail each genetic marker analyzed — including mutation type, zygosity, and clinical significance tiered according to AMP/ACMG 2026 guidelines — and is designed for direct interpretation by your treating oncologist or hematologist. While our clinical counselors provide telephonic result overview and can clarify technical terminology, definitive clinical interpretation and any subsequent treatment modifications must be performed by your licensed specialist physician. Reports are transmitted via encrypted digital channels compliant with UAE PDPL data privacy standards, and hard copies can be collected or couriered upon request.
تُصدر النتائج خلال 6 أيام عمل مع استشارة هاتفية مجانية لتوضيح التقرير، على أن يتولى طبيب الأورام المعالج التفسير السريري النهائي.
Book Your CLL Mutations Comprehensive Panel Today
Home Collection | 8 AM – 11 PM | ISO-Certified | 1500 AED
WhatsApp: +971 54 548 8731DHA Facility License 9834453 | ISO 9001:2015 (INT/EGQ/2509DA/3139)
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians